Karyopharm Therapeutics | KPTI - Assets


Karyopharm Therapeutics reported $96.23M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Abbott USD 86.71B 2.53B Dec/2025
Amgen USD 90.59B 445M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
BioCryst Pharmaceuticals USD 514.16M 67.73M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
J&J USD 199.21B 6.39B Dec/2025
Karyopharm Therapeutics USD 96.23M 8.65M Sep/2025
MacroGenics USD 256.85M 13.92M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Novartis USD 110.95B 3.66B Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Takeda JPY 15.41T 938.47B Dec/2025
Tectonic Therapeutic USD 261.04M 15.96M Dec/2025
TG Therapeutics USD 1.06B 38.23M Dec/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Xencor USD 875.5M 6.68M Dec/2025